Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug following its ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The results bring Eli Lilly's pill orforglipron one step closer to becoming a new, needle-free alternative in the booming ...

Eli Lilly said its experimental drug, orforglipron, helped people with Type 2 diabetes lower their blood sugar and lose ...

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.